Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
Want to see TSE:LEXT full AI Analyst Report?
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.34
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$1.38M
Enterprise ValueC$97.61K
Total Cash (Recent Filing)C$278.52K
Total Debt (Recent Filing)C$8.00K
Price to Earnings (P/E)―
Beta-0.04
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageHaving no reported debt materially reduces solvency and refinancing risk over the medium term. With zero leverage, the company has structural flexibility to fund near-term operations via equity or strategic partnerships without fixed interest obligations, which is important given current cash burn.
Historic Revenue/Gross ProfitPrior periods of revenue and positive gross profit show the business model has produced operating revenue historically. This indicates operational capability and reduces the binary risk that the firm is purely non-operational, implying that with execution or funding it can redeploy assets to regain revenue.
Improving FCF TrendAn improving trailing‑12‑month free cash flow trajectory, even from negative levels, signals progress toward operational efficiency or lower cash intensity. Sustained improvement would reduce future external financing needs and strengthen long‑term survivability if the trend continues.
Bears Say
Zero Recent RevenueAbsence of recent revenue undermines core business sustainability; without recurrent sales the firm cannot organically cover operating expenses. Over a multi‑month horizon this forces reliance on financing or asset sales, making long‑term viability dependent on capital markets or a material operational turnaround.
Persistent Cash BurnConsistent negative operating cash flow creates ongoing runway pressure and increases dependence on external funding. That constrains strategic options, limits ability to invest in growth or exploration, and raises dilution or restructuring risk if the company cannot convert operational improvements into positive cash generation.
Negative Returns & Volatile EquityPersistently negative ROE and equity volatility indicate the company has not compounded shareholder value and faces an unstable capital base. This weakens investor confidence and can raise future capital costs or restrict access to financing, limiting the firm's ability to execute longer‑term strategies.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.04 and its highest was C$0.34 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$1.38M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Sep 21, 2026 which is in 92 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Apr 03, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.016.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Based in Vancouver, Canada, Lexston Life Sciences Corp. operates as a biotechnology firm. The company offers comprehensive cannabis testing and research services across Canada, in addition to analytical evaluations for cannabis, pathogens, and toxins. A significant focus for Lexston involves the development and validation of standardized production methods for plant-derived psychedelics, with a view to supporting mental health and wellness initiatives.
Technical Analysis
Options Prices
Currently, No data available
---